North America Vet Compounding Pharmacies Market Size, Share, Growth, and Regional Forecast, 2025 - 2032

North America vet compounding pharmacies market size is valued at US$1.6 billion in 2025 and projected to reach US$2.7 billion growing at a CAGR of 7.6% during the forecast period from 2025 to 2032.

The North American veterinary compounding pharmacies industry is experiencing significant growth due to rising pet ownership, increasing prevalence of chronic and complex animal health conditions, and growing demand for personalized, flavor-tailored medications. The U.S. dominates the region, driven by advanced veterinary care infrastructure and high pet-owner awareness, while Canada is emerging, with increased adoption of compounded therapies.

• Increasing pet ownership across the U.S. and Canada is driving demand for veterinary care and compounded medications.
• The U.S. leads North America due to advanced veterinary infrastructure, high disposable income, and pet health awareness. It accounts for the largest share of veterinary compounding pharmacy revenue in the region.
• Canada is witnessing a rise in the adoption of compounded medications, driven by expanding veterinary clinics, increased pet ownership, and greater awareness of tailored therapy options for animals.
• CNS agents, including medications for neurological disorders, anxiety, pain management, and behavioral issues in pets, are widely prescribed and frequently compounded to provide species-specific dosages and formulations.

Driver - Higher Level of Veterinary Care Due to Increased Owner Awareness

Factors encouraging the growth of vet compounding pharmacies include the increasing humanization of pets, the expanding adoption of animals in the region, and the growing online influx of medical information. In 2020, almost 84.9 million households had pets, according to the American Pet Product Association and the American Veterinary Medical Association (AVMA). About 34% of households have cats as pets, compared to 50% of U.S. families who own dogs. With ready access to information, pet owners are more aware than ever, increasing demand for high-quality veterinary care. As a result, rising pet adoption is expected to drive demand for vet compounding pharmacies in the future.

Restraints - Safety and Skill-Related Barriers

Both unsafe compounding practices and a lack of trained veterinary professionals constrain the growth of veterinary compounding pharmacies. Contamination during compounding, non-compliance with cGMP standards, and inadequate sterile environments increase the risk of infections, adverse drug reactions, and fatalities. Simultaneously, many veterinarians lack specialized training in veterinary-specific pharmaceutical compounding, leading to errors, incorrect dosing, and potentially harmful prescriptions. Together, these factors limit the safe and widespread adoption of compounded medications, highlighting the critical need for stringent regulatory compliance, proper facility standards, and enhanced interdisciplinary training for veterinary compounding personnel.

Opportunity - Personalized Medications for Chronic Pet Conditions

The rising prevalence of chronic diseases in companion animals, including diabetes, arthritis, and kidney disorders, is creating a significant demand for personalized veterinary medications. Standard dosages often do not meet the unique needs of individual pets, making compounded formulations essential for precise, species-specific treatment. Veterinary compounding pharmacies can develop customized strengths, dosage forms, and administration routes, improving therapeutic efficacy and compliance. These tailored solutions allow pets to receive safer, more effective care, particularly for long-term management of chronic conditions. As the awareness grows among pet owners, the demand for individualized, high-quality compounded medications continues to expand across North America.

By Product Type Insights

The CNS Agents segment dominates the North America veterinary compounding pharmacies market due to the high prevalence of neurological, behavioral, and pain-related disorders in companion animals. Pets often require precise, species-specific dosing for conditions such as anxiety, epilepsy, and chronic pain, which cannot always be met with commercially available medications. Veterinary compounding pharmacies provide customized CNS formulations—including oral suspensions, flavored tablets, and transdermal gels that enhance compliance and therapeutic efficacy. The consistent demand from pet owners seeking effective management of behavioral and neurological conditions, combined with the need for personalized dosing, positions CNS agents as the leading and most widely adopted product segment in the market.

By Formulation Insights

The oral formulation segment leads the North America veterinary compounding pharmacies market due to its convenience, ease of administration, and high compliance among companion animals. Flavored suspensions, chewable tablets, and species-specific oral solutions allow precise dosing for chronic conditions such as diabetes, arthritis, and behavioral disorders, which require long-term therapy. Oral formulations reduce stress for pets and simplify medication administration for owners, making them more practical than injectables or other specialized forms. Additionally, their versatility across multiple therapeutic categories, including CNS agents, anti-infectives, and hormones, further drives demand, establishing oral formulations as the preferred and highest-share segment in the veterinary compounding market.

U.S. Vet Compounding Pharmacies Market Trends

The U.S. veterinary compounding pharmacies market is experiencing robust growth, driven by rising pet ownership, the growing prevalence of chronic animal diseases, and demand for personalized medications. Flavor-tailored oral formulations, small-batch compounding, and sterile injectable drugs are gaining prominence to enhance compliance and therapeutic outcomes. Regulatory oversight from the FDA, including cGMP certification for outsourcing facilities, ensures safety and quality, boosting market confidence. Advances in technology, such as automated compounding and precision dosing equipment, are improving efficiency and consistency. Additionally, expanding veterinary clinics, telemedicine services, and awareness of specialized treatments are driving the adoption of compounded medications, positioning the U.S. as a leading global market.

The North American veterinary compounding pharmacies market is highly competitive, with a mix of large-scale compounding facilities, regional players, and specialized boutique pharmacies. Key players focus on differentiating through customized formulations, flavor-enhanced medications, sterile injectables, and advanced oral preparations to meet diverse veterinary needs. Strategic partnerships with veterinary clinics, hospitals, and telemedicine providers enhance market reach and client retention.

Key Industry Developments:

• In January 2025, Revelation Pharma launched its new animal-focused division, Revelation Animal Health, a dedicated arm aimed at serving the unique health needs of animals across the nation.